Cutaneous complications of anti-hypertensive drugs;Complications cutanées des traitements anti-hypertenseurs

Revue Medicale Suisse

Volumn 1, Issue 32, 2005, Pages 2093-2097

  Grünenwald, Michèle ^a   Pechère Bertschi, Antoinette ^a   Prins, Christa ^b   Pechère, Marc ^c  

^a HUG   (Switzerland)

^b HUG   (Switzerland)

^c LA TOUR HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; MINOXIDIL; NIFEDIPINE; SPIRONOLACTONE; SULFAMIDE DERIVATIVE; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT; VERAPAMIL;

ALOPECIA; ANGIONEUROTIC EDEMA; CHLOASMA; ECZEMA; EDEMA; ERYTHEMA MULTIFORME; FLUSHING; GRAFT VERSUS HOST REACTION; GYNECOMASTIA; HUMAN; HYPERTENSION; HYPERTRICHOSIS; LICHEN; LICHEN PLANUS; LUPUS ERYTHEMATOSUS; MACULOPAPULAR RASH; MOUTH INFLAMMATION; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PRESCRIPTION; PSORIASIS; PURPURA; PUSTULOSIS; RAYNAUD PHENOMENON; REVIEW; SIDE EFFECT; TELANGIECTASIA; URTICARIA; VASCULITIS; VIRUS INFECTION; DRUG ERUPTION;

ANTIHYPERTENSIVE AGENTS; DRUG ERUPTIONS; HUMANS;

EID: 33644634046     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Thestrup-Pedersen K. Adverse reactions in the skin from anti-hxpertensive drugs. Dan Med Bull 1987;34 (Suppl 1):3-5.
2. Nigen S, Knowles SR, Shear NH. Drug eruptions: Approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003;2:278-99.
3. Frishman WH, Brosnan B.D, Grossman M, Dasgupta D, Sun DK. Adverse dermatologic effects of cardiovascular drug therapy: Part II. Cardiology in review. 2002;10: 285-300.
4. Gold MH, Holy AK, Roenigk HH Jr. Beta-blocking drugs and psoriasis. A review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol 1988;19:837-41.
5. Marshall AJ, Roberts CJ, Barritt DW. Raynaud's phenomenon as side effect of beta-blockers in hypertension. Br Med J 1976;19:11498-9.
6. Ioulios P, Charalampos M, Efrossini T. The spectrum of cutaneous reactions associated with calcium antagonists: A review of the literature and the possible etiopathogenic mechanisms. Dermatol Online J 2003;9:6.
7. Knowles S, Gupta AK, Shear NH. The spectrum of cutaneous reactions associated with diltiazem: Three cases and a review of the literature. J Am Acad Dermatol 1998;38:201-6.
8. Joly P. Abstract Ann Dermatol Venereol Rouen 2005. Sous presse.
9. Ellis S, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: A community-based study. J Periodontol 1999;70:63-7.
10. Brenner S, Ruocco V, Bialy-Golan A, et al. Pemphigus and pemphigoid-like effects of nifedipine on in vitro cultured normal human skin explants. Int J Dermatol 1999;38:36-40.
11. Magro CM, Crowson AN. Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: A hypothesis. Hum Pathol 1996;27:125-32.
12. Craig K, Svensson, Edward W. Cowen and Anthony A. Gaspari. Cutaneous Drug Reactions. Pharm Rev 2001; 53:357-79.
13. Moore DE. Drug-induced cutaneous photosensitivity: Incidence, mechanism, prevention and management. Drug Saf 2002;25:345-72.
14. Addo HA, Ferguson J, Frain-Bell W. Thiazide-induced photosensitivity: A study of 33 subjects. Br J Dermatol 1987;116:749-60.
15. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985;103:49-51.
16. Hughes BR, Cunliffe WJ. Tolerance of spironolactone. Br J Dermatol 1988;118:687-91.
17. Thestrup-Pedersen K. Adverse reactions in the skin from anti-hypertensive drugs. Dan Med Bull 1987;34 (Suppl 1):3-5.
18. Pillans PI, Coulter DM, Black P. Angiooedema and urticaria with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 1996;51:123-6.
19. Zafar H, Israili, W. Dallas Hall. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med 1992;117:234-42.
20. Scholzen TE, Stander S, Riemann H, Brzoska T, Luger TA. Modulation of cutaneous inflammation by angiotensin-converting enzyme. J Immunol 2003;170:3866-73.
21. Postore L. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999;100:1646-52.
22. Molteni A, Ward WF, Ts'ao CH, et al. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Des 2003;9:751-61.
23. Cha YJ, Pearson VE. Angioedema due to losartan. Ann Pharmacother 1999;33:936-8.
24. van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998;158:2063-5.
25. Castells X, Rodoreda I, Pedros C, Cereza G, Laporte JR. Drug points: Dysgeusia and burning mouth syndrome by eprosartan. BMJ 2002;325:1277.
26. Marquart-Elbaz C, Grosshans E, Lipsker D, Lipsker D. Sartans, angiotensin II receptor antagonists, can induce psoriasis. Br J Dermatol 2002;147:617-8.